COL3A1

NEWTON, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today announced it has entered into definitive agreements to reacquire worldwide development, commercialization and economic rights to OLPRUVA™ (sodium phenylbutyrate) from Relief Therapeutics, excluding the European Union, Liechtenstein, San Marino, Vatican City, Norway, Iceland, Principality of Monaco, Andorra, Gibraltar, Switzerland, United Kingdom, Albania, Bosnia, Kosovo, Montenegro, Serbia and North Macedonia (Geographical Europe). OLPRUVA™ is approved in the U.S. for the treatment of certain urea cycle disorders (UCDs). Under the prior Collaboration and License Agreement (CLA) between the parties, Acer would have paid Relief 60% of Acer's OLPRUVA™ net profits in the U.S., Canada, Brazil, Turkey and Japan (the Acer territories), while Acer would have received a 15% royalty on Relief’s net sales in the rest of the world (the Relief territories). Acer and Relief have now agreed to terminate the CLA, where Acer is no longer required to pay Relief 60% of OLPRUVA™ net profits in the Acer territories and have regained all development and commercialization rights in rest of the world, excluding the Geographical Europe. In return, Relief will receive an upfront payment by Acer of $10 million, to be made within 5 business days of the signature date, with an additional payment of $1.5 million due on the first-year anniversary of the $10 million payment. Acer has also agreed to pay a 10% royalty on net sales in the Acer territories, and 20% of any value received by Acer from certain third parties relating to OLPRUVA™ licensing or divestment rights, all of the foregoing which are capped at $45 million, for total payments to Relief of up to $56.5 million. Additionally, Acer and Relief have entered into a new Exclusive License Agreement (ELA) in which Relief will retain development and commercialization rights for OLPRUVA™ in the Geographical Europe, where Acer will have the right to receive a royalty of up to 10% of the net sales of OLPRUVA™. “Regaining exclusive worldwide rights to OLPRUVA™ without profit sharing, subject only to Relief's rights in the Geographical Europe, unlocks value for Acer as we continue the U.S. launch of OLPRUVA™ and begin to provide treatments to UCD patients in need,” said Chris Schelling, CEO and Founder of Acer. “Reacquiring greater economic rights to OLPRUVA™ allows Acer to reinvest more capital into potential lifecycle expansion opportunities for OLPRUVA™, in additional inborn errors of metabolism, such as Maple Syrup Urine Disease and other potential indications.” “We are very happy to have restructured our collaboration with Acer Therapeutics which we believe will benefit those suffering from UCDs and other potential rare metabolic conditions,” said Jack Weinstein, CEO of Relief Therapeutics. “Our collective goal with Acer is to maximize the global commercialization of OLPRUVA™ to ensure as many patients as possible will access this much needed, differentiated and convenient alternative.” Additional information regarding the termination of the March 2021 CLA and execution of the new ELA for European rights is available on form 8-K at . OLPRUVA™: Now Available by Prescription in U.S. ACER-001 (sodium phenylbutyrate) was approved for the treatment of certain UCDs in December 2022 and is marketed under the brand name, OLPRUVA™. OLPRUVA™ (sodium phenylbutyrate) for oral suspension is a prescription medicine used along with certain therapy, including changes in diet, for the long-term management of adults and children weighing 44 pounds (20 kg) or greater and with a BSA of 1.2 m2 or greater, with UCDs, involving deficiencies of CPS, OTC, or AS.1 Please see full Prescribing Information, including Patient Information. Important Safety Information Certain medicines may increase the level of ammonia in the blood or cause serious side effects when taken during treatment with OLPRUVA™. Tell your doctor about all the medicines you or your child takes, especially if you or your child takes corticosteroids, valproic acid, haloperidol, and/or probenecid. OLPRUVA™ can cause serious side effects, including: 1) nervous system problems (neurotoxicity) such as, sleepiness, tiredness, lightheadedness, vomiting, nausea, headache, and/or confusion, 2) low potassium levels in your blood (hypokalemia) and 3) conditions related to swelling (edema). OLPRUVA™ contains salt (sodium), which can cause swelling from salt and water retention. Tell your doctor right away if you or your child get any of these symptoms. Your doctor may do certain blood tests to check for side effects during treatment with OLPRUVA. If you have certain medical conditions such as heart, liver or kidney problems, are pregnant/planning to get pregnant or breast-feeding, your doctor will decide if OLPRUVA™ is right for you. The most common side effects of OLPRUVA™ include absent or irregular menstrual periods, decreased appetite, body odor, bad taste or avoiding foods you ate prior to getting sick (taste aversion). These are not all of the possible side effects of OLPRUVA™. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. For additional Important Safety Information, see full Prescribing Information, Patient Package Insert and discuss with your doctor. About Acer Therapeutics Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. In the U.S., OLPRUVA™ (sodium phenylbutyrate) is approved for the treatment of UCDs involving deficiencies of CPS, OTC, or AS. Acer is also advancing a pipeline of investigational product candidates for rare and life-threatening diseases, including: OLPRUVA™ (sodium phenylbutyrate) for treatment of various disorders, including Maple Syrup Urine Disease (MSUD); and EDSIVO™ (celiprolol) for treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation. For more information, visit . References OLPRUVA™ (sodium phenylbutyrate) for oral suspension. Prescribing information. Newton, MA: Acer Therapeutics Inc. Acer Forward-Looking Statements This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release are forward-looking statements. Examples of such statements include, but are not limited to, expected payments between Acer and Relief in connection with the ELA and terminated CLA, the impact of the revised business arrangement between Acer and Relief on the Company and the Company’s investment plans related thereto, plans with respect to the U.S. launch of OLPRUVA™, and the possible side effects of OLPRUVA™. Additionally, the Company’s effort to advance a pipeline of investigational product candidates and related plans and expectations is an example of such forward-looking statements. Our efforts to commercialize OLPRUVA™ for oral suspension in the U.S. for the treatment of certain patients with UCDs involving deficiencies of CPS, OTC, or AS are at an early stage, we currently do not have fully developed marketing and sales capabilities, and there is no guarantee that we will be successful in our commercialization efforts. Our pipeline products (including OLPRUVA™ for indications other than UCDs) are under investigation and their safety and efficacy have not been established and there is no guarantee that any of our investigational products in development will receive health authority approval or become commercially available for the uses being investigated. We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the availability of financing to fund our commercialization efforts, our pipeline product development programs and general corporate operations as well as risks related to drug development and the regulatory approval process, including the timing and requirements of regulatory actions. We disclaim any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. You should review additional disclosures we make in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. You may access these documents for no charge at . Corporate and IR Contacts Harry Palmin Chief Financial Officer Acer Therapeutics Inc. investors@acertx.com +1-844-902-6100 Nick Colangelo Gilmartin Group nick@gilmartinIR.com +1-332-895-3226

OLPRUVA™ (sodium phenylbutyrate) kits now available in all dosage strengths and ready to ship to patients NEWTON, Mass., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update. “The second quarter of 2023 marked continued progress for Acer as we execute on our OLPRUVA™ launch strategy,” said Chris Schelling, CEO and Founder of Acer. “We are pleased to offer OLPRUVA™ in the U.S. to certain UCD patients as a novel alternative option to current treatments that was specifically designed for palatability and convenience.1,2 With OLPRUVA™ kits now available in all dosage strengths, we are committed to supporting patients from initial prescription to support throughout the treatment process and look forward to making OLPRUVA™ available to patients in need.” Program and Corporate Highlights OLPRUVA™ (sodium phenylbutyrate) for oral suspension OLPRUVA™ kits are now available in all dosage strengths and ready to ship to patients A dedicated OLPRUVA™ Navigator Team at CVS Specialty is now available to provide prescription fulfillment support throughout the treatment process; healthcare provider and patient resources are also now available at and Acer Therapeutics is in discussions with both commercial and government payers and is actively engaged with the major pharmacy benefits managers (PBM) and group purchasing organizations (GPO) representing a substantial majority of covered lives Corporate Ended Q2 2023 with $1.6 million in cash and cash equivalents. Acer believes its cash and cash equivalents available as of June 30, 2023 will be sufficient to fund its anticipated operating and capital requirements through mid-Q3 2023 Anticipated Milestones (Subject to Available Capital) Q3 2023: Acer expects to begin attaining OLPRUVA™ commercial insurance coverage in Q3 2023 Q3 2023: Acer expects to begin attaining insurance coverage for OLPRUVA™ Medicaid patients starting in Q3 2023 H1 2024: Acer anticipates enrollment completion in H1 2024 of its pivotal Phase 3 DiSCOVER trial of EDSIVO™ in patients with COL3A1-positive vEDS Acer also intends to pursue additional opportunities for potential OLPRUVA™ label expansion, including the potential for additional dosage strengths to address patients with lower weights/body surface areas, and potential administration using a gastrostomy tube (G-tube) Q2 2023 Financial Results Cash Position. Cash and cash equivalents were $1.6 million as of June 30, 2023, compared to $2.3 million as of December 31, 2022. Acer believes its cash and cash equivalents at June 30, 2023 will be sufficient to fund its anticipated operating and capital requirements through the middle of the third quarter of 2023. Research and Development Expenses. Research and development expenses were $1.4 million, net of collaboration funding of $0.6 million, for the three months ended June 30, 2023, as compared to $3.4 million, net of collaboration funding of $1.6 million, for the three months ended June 30, 2022. This decrease of $2.0 million was primarily due to decreases in expenses for clinical studies, employee-related expenses, expenses for consulting and professional services, and contract manufacturing expenses. Research and development expenses related to ACER-001 decreased in the three months ended June 30, 2023, resulting in a decrease in the recognition of the collaboration funding from the Collaboration Agreement with Relief. Research and development expenses for the three months ended June 30, 2023 were comprised of $1.0 million related to EDSIVOTM; $0.6 million related to ACER-001, offset by $0.6 million of collaboration funding; $0.2 million related to ACER-801; and $0.2 million related to other development activities. General and Administrative Expenses. General and administrative expenses were $2.9 million, net of collaboration funding of $1.4 million, for the three months ended June 30, 2023, as compared to $3.6 million, net of collaboration funding of $3.3 million, for the three months ended June 30, 2022. This decrease of $0.7 million was primarily due to decreases in marketing expenses, expenses for consulting and professional services, and employee-related expenses. General and administrative expenses related to ACER-001 decreased in the three months ended June 30, 2023, resulting in a decrease in the recognition of the collaboration funding from the Collaboration Agreement with Relief. Net Loss. Net loss for the three months ended June 30, 2023 was $8.1 million, or $0.33 net loss per share (basic and diluted), compared to a net loss of $2.7 million, or $0.17 net loss per share (basic and diluted), for the three months ended June 30, 2022. For additional information, please see Acer’s Quarterly Report on Form 10-Q filed today with the Securities and Exchange Commission (SEC). About Acer Therapeutics Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. In the U.S., OLPRUVA™ (sodium phenylbutyrate) is approved for the treatment of UCDs involving deficiencies of CPS, OTC, or AS. Acer is also advancing a pipeline of investigational product candidates for rare and life-threatening diseases, including: OLPRUVA™ (sodium phenylbutyrate) for treatment of various disorders, including Maple Syrup Urine Disease (MSUD); and EDSIVO™ (celiprolol) for treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation. For more information, visit . References OLPRUVA™ (sodium phenylbutyrate) for oral suspension. Prescribing information. Newton, MA: Acer Therapeutics Inc. Appel LE, Shockey JR, Schelling DC, inventors; Acer Therapeutics Inc, assignee. Palatable compositions including sodium phenylbutyrate and uses thereof. US patent 11,154,521 (B2). October 26, 2021. Acer Forward-Looking Statements This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release are forward-looking statements. Examples of such statements include, but are not limited to, statements about plans and strategy for the commercialization of OLPRUVA™ for oral suspension in the U.S. for the treatment of certain patients with certain UCDs, including progress with respect to discussions with commercial and government insurance providers, physicians outreach and awareness, and patient support and fulfillment, statements with respect to our EDSIVO clinical trial for patients with vEDS, including enrollment and timing milestones related thereto, statements about our anticipated 2023 milestones, statements about our investment of OLPRUVA revenue, and statements about our capital requirements and sufficiency and duration of our current cash and cash equivalents. Our efforts to commercialize OLPRUVA™ for oral suspension in the U.S. for the treatment of certain patients with UCDs involving deficiencies of CPS, OTC, or AS are at an early stage, we currently do not have fully developed marketing, sales or distribution capabilities, and there is no guarantee that we will be successful in our commercialization efforts. Our pipeline products (including OLPRUVA™ for indications other than UCDs as well as EDSIVO™ and ACER-801) are under investigation and their safety and efficacy have not been established and there is no guarantee that any of our investigational products in development will receive health authority approval or become commercially available for the uses being investigated. We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the availability of financing to fund our commercialization efforts, our pipeline product development programs and our general corporate operations as well as risks related to drug development and the regulatory approval process, including the timing and requirements of regulatory actions. We disclaim any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. You should review additional disclosures we make in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. You may access these documents for no charge at ACER THERAPEUTICS INC. CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Three Months Ended June 30, 2023 2022 Operating expenses: Research and development (net of collaboration funding of $600,072 and $1,648,631 in the three months ended June 30, 2023 and 2022, respectively) $ 1,440,717 $ 3,426,773 General and administrative (net of collaboration funding of $1,404,695 and $3,257,701 in the three months ended June 30, 2023 and 2022, respectively) 2,853,760 3,638,073 Loss from operations (4,294,477 ) (7,064,846 ) Other income (expense), net: Costs of debt issuance — (200,129 ) Loss on extinguishment of debt (350,000 ) — Changes in fair value of debt instruments (loss) gain (2,806,538 ) 4,729,460 Interest and other income (expense), net (639,610 ) (139,234 ) Foreign currency transaction (loss) gain (95 ) 7,713 Total other income (expense), net (3,796,243 ) 4,397,810 Net loss $ (8,090,720 ) $ (2,667,036 ) Net loss per share - basic $ (0.33 ) $ (0.17 ) Weighted average common shares outstanding - basic 24,462,895 15,273,707 Net loss per share - diluted $ (0.33 ) $ (0.30 ) Weighted average common shares outstanding - diluted 24,462,895 17,681,400 SELECTED BALANCE SHEET DATA (Unaudited): June 30, December 31, 2023 2022 Cash and cash equivalents $ 1,553,416 $ 2,329,218 Inventory $ 4,600,618 $ — Prepaid expenses $ 583,339 $ 759,292 Deferred financing costs $ — $ 408,000 Other current assets $ 14,638 $ 20,188 Property and equipment, net $ 54,273 $ 214,578 Total assets $ 14,648,276 $ 11,624,226 Accounts payable and accrued expenses $ 10,438,490 $ 7,470,674 Promissory Note payable to an officer $ 1,000,000 $ — Deferred collaboration funding, total $ 4,547,198 $ 8,412,971 SWK Loans payable, at fair value $ 17,986,848 $ 5,567,231 Convertible note payable, at fair value $ 13,078,200 $ 6,047,532 Total liabilities $ 47,894,494 $ 28,385,498 Total stockholders’ deficit $ (33,246,218 ) $ (16,761,272 ) Corporate and IR Contact Jim DeNike Acer Therapeutics Inc. jdenike@acertx.com +1-844-902-6100 Nick Colangelo Gilmartin Group nick@gilmartinIR.com +1-332-895-3226

U.S. OLPRUVA™ launch progressing ahead of schedule with drug-in-channel now anticipated in mid-June 2023NEWTON, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the first quarter ended March 31, 2023 and provided a corporate update. “The first quarter of 2023 was marked by considerable progress and a number of significant milestones in support of our commercial launch of OLPRUVA™, an innovative treatment option for patients with certain Urea Cycle Disorders (UCDs),” said Chris Schelling, CEO and Founder of Acer. “As a result, we are now ahead of our anticipated launch schedule with drug-in-channel expected in mid-June 2023. We have also made significant progress in the other key areas of our OLPRUVA™ commercialization strategy, including ongoing discussions with commercial and government insurance providers, physician outreach and awareness, and patient support and fulfillment. We look forward to continued progress in all of these areas and to delivering OLPRUVA™ to patients in mid-June 2023.” Mr. Schelling added, “We have also started a broad outreach program to physicians who treat vascular Ehlers-Danlos Syndrome (vEDS) patients and have received overwhelming support for our ongoing Decentralized Study of Celiprolol on vEDS-related Event Reduction (DiSCOVER) Phase 3 EDSIVO™ (celiprolol) clinical trial. As a result, we anticipate enrollment in this trial to be completed by the end of this year. All of these activities are subject to additional capital.” Q1 2023 and Recent Highlights OLPRUVA™ (sodium phenylbutyrate) for oral suspension In March 2023, Acer announced the presentation of data at the Annual Meeting of the Society for Inherited Metabolic Disorders (SIMD) from a survey of UCD healthcare providers sponsored by Acer that indicated taste and odor were the most important attributes when considering treatment options and treatment adherenceAlso at the SIMD Annual Meeting, Acer representatives met with 33 metabolic treatment providers -- including nurse practitioners, registered dieticians, and physicians – from 24 metabolic treatment centers throughout the U.S. Of those metabolic treatment providers surveyed by Acer, 70% expressed a high interest in treating at least one of their patients with OLPRUVA™ in 2023In preparation for OLPRUVA™’s planned drug-in-channel in mid-June 2023, the Company is in discussions with the major pharmacy benefits managers (PBM) and group purchasing organizations (GPO) representing a substantial majority of covered livesAcer has also established a responsible and competitive pricing strategy designed to offer UCD patients a new treatment option at a significant discount to RAVICTI® while delivering predictable pricing that will not increase beyond the rate of inflation. Acer also plans to invest a portion of OLPRUVA™ revenue back into additional solutions aimed at improving outcomes for UCD patientsFinally, Acer has established and staffed its patient support program, Navigator by Acer Therapeutics, that includes a suite of services designed to provide streamlined and efficient prescription management -- including benefits verification, education, and home delivery -- and personalized support for OLPRUVA™ patients EDSIVO™ (celiprolol) Acer continues to enroll patients in its ongoing, pivotal Phase 3 Decentralized Study of Celiprolol on vEDS-related Event Reduction (DiSCOVER) clinical trial of EDSIVO™ (celiprolol) in patients with COL3A1-positive vEDS. The double-blind portion of the DiSCOVER trial is designed to include an interim analysis conducted after 28 vEDS related events, which could occur as early as approximately 18 months after completion of full enrollment; and end if statistical significance is reached after 46 vEDS-related events, estimated to occur as early as approximately 40 months after completion of full enrollment ACER-801 In March 2023, Acer announced topline results from its Phase 2a trial evaluating ACER-801 (osanetant) for the treatment of moderate to severe Vasomotor Symptoms (VMS) associated with menopause. The trial showed that ACER-801 was generally safe and well-tolerated but did not achieve statistically significant decrease in frequency or severity of hot flashes in postmenopausal women. As a result, Acer has paused the ACER-801 program until it has completed a thorough review of the full data set from the Phase 2a trial Corporate Ended Q1 2023 with $6.4 million in cash and cash equivalents. Acer believes its cash and cash equivalents available at March 31, 2023, together with $0.4 million from Acer’s ATM facility subsequent to March 31, 2023, will be sufficient to fund its anticipated operating and capital requirements into late in the second quarter of 2023 Anticipated Milestones (Subject to Available Capital) Mid-to-Late May 2023: Acer expects to publish OLPRUVA™’s list price, or wholesale acquisition cost (WAC), in mid-to-late May 2023June 2023: Acer anticipates OLPRUVA™ drug availability in mid-June 20232H 2023: Acer expects to begin attaining OLPRUVA™ commercial insurance coverage in 2H 2023Q3 2023: Acer expects to begin attaining insurance coverage for OLPRUVA™ Medicaid patients starting in Q3 2023Year End 2023: Acer anticipates enrollment completion by end of 2023 in its ongoing, pivotal Phase 3 DiSCOVER trial of EDSIVO™ in patients with COL3A1-positive vEDSAcer also intends to pursue additional opportunities for potential OLPRUVA™ label expansion, including the potential for additional dosage strengths to address patients with lower weights/body surface areas, and potential administration using a gastrostomy tube (G-tube) Q1 2023 Financial Results Cash Position. Cash and cash equivalents were $6.4 million as of March 31, 2023, compared to $2.3 million as of December 31, 2022. Acer believes its cash and cash equivalents available at March 31, 2023, together with $0.4 million from Acer’s ATM facility subsequent to March 31, 2023, will be sufficient to fund its anticipated operating and capital requirements into late in the second quarter of 2023. Research and Development Expenses. Research and development expenses were $2.4 million, net of collaboration funding of $0.7 million, for the three months ended March 31, 2023, as compared to $3.2 million, net of collaboration funding of $3.0 million, for the three months ended March 31, 2022. This decrease of $0.8 million was primarily due to decreases in expenses for contract manufacturing and contract research, employee-related expenses, and clinical studies related to ACER-801 and EDSIVO™. Research and development expenses related to ACER-001 decreased in the three months ended March 31, 2023, resulting in a decrease in the recognition of the collaboration funding from the Collaboration Agreement with Relief. Research and development expenses for the three months ended March 31, 2023 were comprised of $1.0 million related to EDSIVO™; $0.8 million related to ACER-001, offset by $0.7 million of collaboration funding; $0.8 million related to ACER-801; and $0.5 million related to other development activities. General and Administrative Expenses. General and administrative expenses were $2.6 million, net of collaboration funding of $1.1 million, for the three months ended March 31, 2023, as compared to $3.9 million, net of collaboration funding of $2.4 million, for the three months ended March 31, 2022. This decrease of $1.3 million was primarily due to decreases in employee-related expenses, precommercial expenses, and consulting fees. General and administrative expenses related to ACER-001 decreased in the three months ended March 31, 2023, resulting in a decrease in the recognition of the collaboration funding from the Collaboration Agreement with Relief. Net Loss. Net loss for the three months ended March 31, 2023 was $16.3 million, or $0.77 net loss per share (basic and diluted), compared to a net loss of $9.2 million, or $0.64 net loss per share (basic and diluted), for the three months ended March 31, 2022. For additional information, please see Acer’s Quarterly Report on Form 10-Q filed today with the Securities and Exchange Commission (SEC). About Acer TherapeuticsAcer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. In the U.S., OLPRUVA™ (sodium phenylbutyrate) is approved for the treatment of urea cycle disorders (UCDs) involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). Acer is also advancing a pipeline of investigational product candidates for rare and life-threatening diseases, including: OLPRUVA™ (sodium phenylbutyrate) for treatment of various disorders; EDSIVO™ (celiprolol) for treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; and ACER-801 (osanetant) for treatment of Vasomotor Symptoms (VMS), post-traumatic stress disorder (PTSD) and prostate cancer. For more information, visit www.acertx.com. Acer Forward-Looking StatementsThis press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release are forward-looking statements. Examples of such statements include, but are not limited to, statements about plans and strategy for the commercialization of OLPRUVA™ for oral suspension in the U.S. for the treatment of certain patients with certain UCDs, including launch schedule and timing of drug in channel, progress with respect to discussions with commercial and government insurance providers, physicians outreach and awareness, and patient support and fulfillment, statements with respect to our EDSIVO clinical trial for patients with vEDS, including enrollment and timing milestones related thereto, statements about our anticipated 2023 milestones, statements about our investment of OLPRUVA revenue, and statements about our capital requirements and sufficiency and duration of our current cash and cash equivalents. Our efforts to commercialize OLPRUVA™ for oral suspension in the U.S. for the treatment of certain patients with UCDs involving deficiencies of CPS, OTC, or AS are at an early stage, we currently do not have fully developed marketing, sales or distribution capabilities, and there is no guarantee that we will be successful in our commercialization efforts. Our pipeline products (including OLPRUVA™ for indications other than UCDs as well as EDSIVO™ and ACER-801) are under investigation and their safety and efficacy have not been established and there is no guarantee that any of our investigational products in development will receive health authority approval or become commercially available for the uses being investigated. We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the availability of financing to fund our commercialization efforts, our pipeline product development programs and our general corporate operations as well as risks related to drug development and the regulatory approval process, including the timing and requirements of regulatory actions. We disclaim any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. You should review additional disclosures we make in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. You may access these documents for no charge at http://www.sec.gov. ACER THERAPEUTICS INC.CONSOLIDATED STATEMENTS OF OPERATIONS(Unaudited) Three Months Ended March 31, 2023 2022 Operating expenses: Research and development (net of collaboration funding of $718,410 and $2,999,371 in the three months ended March 31, 2023 and 2022, respectively)$2,421,120 $3,171,639 General and administrative (net of collaboration funding of $1,142,596 and $2,372,175 in the three months ended March 31, 2023 and 2022, respectively) 2,568,181 3,875,601 Loss from operations (4,989,301) (7,047,240) Other income (expense), net: Costs of debt issuance (577,225) (1,168,065)Loss on extinguishment of debt (8,191,494) — Changes in fair value of debt instruments (2,211,685) (962,400)Interest and other income (expense), net (286,537) (2,838)Foreign currency transaction (loss) gain (24,464) 1,539 Total other income (expense), net (11,291,405) (2,131,764) Net loss$(16,280,706) $(9,179,004) Net loss per share - basic and diluted$(0.77) $(0.64) Weighted average common shares outstanding - basic and diluted 21,113,166 14,310,244 SELECTED BALANCE SHEET DATA (Unaudited): March 31, December 31, 2023 2022 Cash and cash equivalents $6,379,977 $2,329,218 Inventory $412,038 $— Prepaid expenses $800,777 $759,292 Deferred financing costs $— $408,000 Other current assets $14,638 $20,188 Property and equipment, net $202,097 $214,578 Total assets $15,672,096 $11,624,226 Accounts payable and accrued expenses $5,918,621 $7,470,674 Deferred collaboration funding $6,551,965 $8,412,971 SWK Loans payable, at fair value $17,057,110 $5,567,231 Convertible note payable current, at fair value $11,392,167 $6,047,532 Total liabilities $41,785,695 $28,385,498 Total stockholders’ deficit $(26,113,599) $(16,761,272) Corporate and IR Contact Jim DeNikeAcer Therapeutics Inc.jdenike@acertx.com+1-844-902-6100 Nick ColangeloGilmartin Groupnick@gilmartinIR.com+1-332-895-3226